USA: Expert panel recommended prioritizing Pfizer and Moderna vaccines over Johnson & Johnson's.


USA: Expert panel recommended prioritizing Pfizer and Moderna vaccines over Johnson & Johnson's.

The vote, which came out 15 to 0, was based on the weakest protection and the highest risks of the inoculant, also known as Janssen, which they link with nine reported deaths.

In light of its further protection, a panel of American medical experts advising the Joe Biden administration and the CDC voted Thursday to recommend the COVID-19 mRNA vaccines made by Pfizer and Moderna over the Johnson & Johnson vaccine. Weak and its most significant risks.

The vote was 15-0 in favor of the recommendation. "I would not recommend a Janssen vaccine to members of my family," said Beth Bell, a clinical professor at the University of Washington, referring to the J&J vaccine by an alternate name, about her vote.

"On the other hand, I think we have to recognize that different people make different decisions, and if they are properly informed, I don't think we should eliminate that option," he added.

According to The Washington Post, the health risks linked to the Janssen vaccine are related to blood clots, mainly in young and middle-aged women.

The Centers for Disease Control and Prevention (CDC) called for a vote after more serious clotting cases emerged. So it's that new data seems to show that the rate of these clots has increased since April, although the problem remains rare. Around nine deaths related to the subject have also been reported.

The new data

At least nine people have died from low platelet clotting or thrombosis with thrombocytopenia syndrome (TTS) as of December 9, with about 16 million doses of the vaccine administered, according to new data released by the CDC.

There were 54 cases as of August 31, and 36 required admissions to intensive care. Some of those who did not die had long-term effects such as paralysis.

The highest risks were seen in women ages 30 to 49, where the TTS rate was around one in 100,000.

But the risk is not limited to this demographic, with two of the nine deaths occurring among men. The CDC said the death count might also be underestimated. Overall, about one in seven cases of TSS has been fatal.

The expert panel agreed that the J&J vaccine should remain available to people who, for whatever reason, might reject mRNA vaccines, despite their higher efficacy and lower risks.

They also felt that recommending against J&J entirely would send a negative signal to other parts of the world where it might be the only option available.

"The Johnson and Johnson COVID-19 vaccine is a life-saving tool for people in high-risk populations," argued Penny Heaton, head of global vaccine therapy at J&J.